专栏名称: 亚盛医药

亚盛医药（6855.HK）是一家立足中国、面向全球的处于临床阶段的原创新药研发企业，专注于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台，在细胞凋亡领域的研发颇为突出。

EHA 2024 | Results from 5 Studies Selected for Presentations

亚盛医药 · 公众号 · · 2024-05-16 08:29

正文

Ascentage Pharma (6855.HK) announced today that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024). These posters will feature olverembatinib (HQP1351), the first and only China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor.

The European Hematology Association (EHA) Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. This year, the EHA Hybrid Congress will take place on June 13 - 16, 2024 , in Madrid, Spain.

Dr. Yifan Zhai

Chief Medical Officer of Ascentage Pharma

I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year’s congress, especially the therapeutic potential and clinical value of its drug candidates in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia diseases. We look forward to sharing the detailed results at the congress. In the future, we will continue to advance those development programs in efforts to bring more treatment options to patients around the world.

The five studies to be presented at EHA 2024 are as follows：

Olverembatinib

Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Abstract#

P722

Presentation Type

Poster presentation

Topic

Chronic myeloid leukemia – Clinical

Date & Time

Friday June 14, 2024, 18:00 - 19:00 CEST

Presenting Author

Dr. Elias Jabbour

The University of Texas MD Anderson Cancer Center

Combination of Third Generation TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+ ALL Patients

Abstract#

P427

Presentation Type

Poster presentation

Topic

Acute lymphoblastic leukemia – Clinical

Date & Time

Friday June 14, 2024, 18:00 - 19:00 CEST

Presenting Author

Junjie Chen

Nanfang Hospital, Southern Medical University

Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy

Abstract#

P1862

Presentation Type

e-Poster presentation

Topic

Chronic myeloid leukemia – Clinical

Date & Time

Friday June 14, 2024, 18:00 - 19:00 CEST

Presenting Author

Lu Yu

Peking University People’s Hospital

APG-2575

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Abstract#

P917

Presentation Type

Poster presentation

Topic

Myeloma and other monoclonal gammopathies – Clinical

Date & Time

Friday June 14, 2024, 18:00 - 19:00 CEST

Presenting Author

Dr. Sikander Ailawadhi

Mayo Clinic Florida

APG-5918

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia

EHA 2024 | Results from 5 Studies Selected for Presentations

正文

请到「今天看啥」查看全文